CVS Health corporation is coiled and ready to spring higher

CVS Health beat on top and bottom lines and gave good guidance.
The stock is moving higher on news of another acquisition as well.
Analysts’ sentiment is clear, CVS is the choice above other drugstore chains.
5 stocks we like better than CVS Health.

Jacob Wolinsky ValueWalk

The price action in CVS Health (NYSE:CVS) has been coiling up over the last 15 months and it looks ready to spring higher. The latest earnings report confirms the trend and trajectory of growth and has the market moving higher even now. What this means for investors is a multiple potential expansions that could easily take it up to new all-time highs.

Trading at 10X its earnings it is a value relative to the broad market, it is forecasting growth and it pays twice the yield of the S&P 500. And this dividend is above average in quality as well.

The company is paying out only 24% of its earnings and has such a strong balance sheet it was able to make another acquisition without the use of debt. In this light, not only is the outlook for growth robust, but so too is the outlook for dividend growth. The latest acquisition is Oak Street Health and has yet to pass regulatory approval. Oak Street is a primary care provider that is expected to add $2 billion in EBITDA to annual results by 2026.

It is also expected to result in around $0.500 billion in synergies which will drive margin improvement in the core and Oak Street segments.

CVS has strong Quarter, issues strong guidance

CVS not only had a strong quarter but issued strong guidance as well. The takeaway from the guidance is that results are expected to align with the analyst's expectations without the addition of Signify, which is yet to be completed. As for Q4 2022, the company reported $83.8 billion in revenue for a gain of 9.4% versus last year.

The gains were driven by strength in all segments, led by Health and Pharma, which is good news for competitors like Walgreens Boots Alliance (NASDAQ:WBA) and Rite Aid (NYSE:RAD). CVS revenue also outpaced the Marketbeat.com consensus estimate by 1000 basis points which is also good news for competitors.

Moving down, the company was able to expand margins as well. The operating margin expanded by 290 basis points, and the net income margin by 160 to drive solid bottom-line results. The caveat is that 1-offs in the report mean the $1.99 in earnings is up a slim $0.01 versus last year but outpaced the consensus by $0.06. Turning to the guidance, the company is expecting adjusted EPS of $8.70 to $8.90 versus the $8.86 expected by the analysts.

The analysts prefer CVS health

The Analysts prefer CVS Health to Rite Aid and Walgreens; that is clear. The consensus sentiment for CVS is a Moderate buy compared to Hold for Walgreens and Sell for Rite Aid. The price target for CVS is also favorable, as it implies more than 30% of upside and has been trending higher all year.

There are no new ratings or price targets on Marketbeat.com’s analyst tracking page yet, but they should be consistent with the trend when they come.

The chart of CVS shows a 15-month range with 3 tops and 3 bottoms that are edging lower as they move sideways. This range is a coiled spring of bulls and bears that has this stock ready to unwind. Assuming the analyst's interest remains favorable, this market should unwind to the upside.

The next target for resistance is at the 150-day moving average, a move above that should get it back up near the all-time highs. If the company can progress on its plans, it may move to new highs by summer 2023 and meet or exceed the $119 consensus target.

Author

Jacob Wolinsky

ValueWalk

Jacob Wolinsky is the founder of ValueWalk, a popular investment site. Prior to founding ValueWalk, Jacob worked as an equity analyst for value research firm and as a freelance writer. He lives in Passaic New Jersey with his wife and four children.

GBP/USD dips below 1.3350 with bullish momentum losing steam

The British Pound ticks lower against the US Dollar Monday, attempting to close a seven-day rally, as tensions rise again in the Strait of Hormuz, one of the critical points in the peace process between Washington and Tehran. The GBP/USD pair trades near 1.3340 at the time of writing, down from 1.3387 highs last week, although it maintains a near-term bullish trend intact.

EUR/USD clings to daily gains, still below 1.1450

EUR/USD manages to shrug off the initial bearish tone and advances toward the 1.1440-1.1450 band on Monday, up modestly for the day. Meanwhile, the pair’s mild gains comes on the back of the lack of clear direction in the Greenback in quite an apathetic start to the week.

Gold remains offered below $4,200

Gold comes under fresh downside pressure on Monday, reversing three daily upticks in a row and meeting some initial resistance around the $4,200 mark per troy ounce. Safe-haven demand has shifted toward the US Dollar as renewed tensions surrounding the Strait of Hormuz weigh on market sentiment, limiting the precious metal's upside.

XRP extends decline as risk-off sentiment, fading retail demand weigh

Ripple (XRP) sustains losses on Monday, edging lower toward the short-term $1.10 support. XRP failed to sustain momentum above $1.20 on the previous day, prompting profit-taking amid a broader crypto market drawdown attributed to mild inflows into related digital investment products, declining retail participation and macroeconomic uncertainty.

The US Dollar just beat the Swiss Franc at its own safe-haven game

As the king among safe havens, the Swiss Franc is supposed to benefit from geopolitical shocks such as the Iran war. This time, it didn’t. The Swissie is nearly 6% below January’s peak against the USD after a sharp decline that came along with the war in Iran and the closure of the Strait of Hormuz.

Kevin Warsh offers no policy clues: Why markets still got their answer

Financial markets came to Sintra looking for clues about the Federal Reserve's (Fed) next move. They largely left with confirmation that Fed Chair Kevin Warsh intends to make those clues much harder to find.